Maddi Hebebrand, MC, Associate Editor

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Findings suggest that physical activity alone may not meet the psychosocial needs of vitiligo patients, emphasizing the need for targeted mental health care.

The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.

Discover the latest IPC consensus on psoriasis severity reclassification, enhancing treatment strategies for better patient outcomes and quality of life.

Delgocitinib showed consistent efficacy in atopic, irritant, allergic, and hyperkeratotic forms of chronic hand eczema in pooled trial data.

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

The approval represents the sixth FDA authorization for roflumilast since 2022.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.

Disc Medicine filed an NDA for bitopertin to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients ≥12 years.

The vaccine is designed to stimulate T cell responses against IDO1- and PD-L1–positive cells within the tumor microenvironment.

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Test your knowledge of key words and terms associated with dermatology news from the last month.

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Dermatology Times is recapping our exclusive expert interviews from the month of September.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

Virginia Sybert, MD, emphasizes the importance of judicious genetic testing in pediatric dermatology, advocating for collaboration to enhance patient care.

This episode explores the controversy and lack of clear diagnostic criteria for TSW.

Bristol Myers Squibb expands direct-to-patient pricing for deucravacitinib and apixaban, enhancing access and affordability for patients in need.

By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.

Explore groundbreaking research and insights from the EADV Congress 2025, highlighting advancements in dermatology treatments and patient care.

Rebecca Smith, MD, recently led a Dermatology Times Case-Based Roundtable event on complex cases in atopic dermatitis.